Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2-metastatic breast cancer treated with CDK4/6 inhibitors

被引：0
|
作者：
Antras, Jesus Fuentes
El Ghamrasni, Samah
Zou, Jinfeng
Dou, Aaron
Elliott, Mitchell J.
Avery, Lisa
Bratman, Scott Victor
Cescon, David W.
Bedard, Philippe L.
机构：
[1] Univ Hlth Network, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Univ Toronto, Univ Hlth Network, Dept Biostat, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1075
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients
    Wu, Yifan
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xu, Ye
    Xie, Yuntao
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (03) : 605 - 614
  • [32] Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China
    Deng, Mei
    Chen, Hui-Hui
    Zhu, Xuan
    Luo, Meng
    Zhang, Kun
    Xu, Chun-Jing
    Hu, Kai-Min
    Cheng, Pu
    Zhou, Jiao-Jiao
    Zheng, Shu
    Chen, Yi-Ding
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (06) : 1517 - 1528
  • [33] CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer: Clinico-Pathological Analysis for Determinants of Response
    Maruthi, Vijaya Kadam
    Schultz, Emily
    Knudsen, Erik
    Witkiewicz, Agnieszka
    Hamilton, Deanna
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 136 - 138
  • [34] CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer: Clinico-Pathological Analysis for Determinants of Response
    Maruthi, Vijaya Kadam
    Schultz, Emily
    Knudsen, Erik
    Witkiewicz, Agnieszka
    Hamilton, Deanna
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 136 - 138
  • [35] Characterizing demographics, clinical, and genomic characteristics for US patients with HR+, HER2-metastatic breast cancer following progression on a CDK4 and 6 inhibitor.
    Andre, Fabrice
    Aggarwal, Amit
    Rao, Xi
    Chen, Yongmei
    Beyrer, Julie Kay
    Smyth, Emily Nash
    Guimaraes, Claudia Morato
    Litchfield, Lacey
    Bowman, Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] The educational impact of a curriculum for oncologists on the latest developments in the use of CDK4/6 inhibitors in HR+/HER2-early and metastatic breast cancer
    Dorkhom, N.
    Ragoonath-Cameron, D.
    Bahra, S.
    Patel, U.
    Phoenix, V.
    ANNALS OF ONCOLOGY, 2022, 33 : S159 - S160
  • [37] Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States
    Ravi K. Goyal
    Holly M. Holmes
    Hua Chen
    Susan Abughosh
    Sean D. Candrilli
    Michael L. Johnson
    Breast Cancer Research and Treatment, 2023, 198 : 159 - 166
  • [38] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer at a Single Cancer Center
    Knudsen, Erik S.
    Schultz, Emily
    Hamilton, Deanna
    Attwood, Kris
    Edge, Stephen
    O'Connor, Tracey
    Levine, Ellis
    Witkiewicz, Agnieszka K.
    ONCOLOGIST, 2022, 27 (08): : 646 - 654
  • [39] Real-world experience with CDK4/6 inhibitors for metastatic HR+/HER2-breast cancer at a single cancer center
    Milovic-Kovacevic, M.
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    Poparic-Bandjur, B.
    BREAST, 2023, 68 : S115 - S115
  • [40] Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2-metastatic breast cancer in the United States: A SEER-Medicare population-based study
    Goyal, Ravi K.
    Chen, Hua
    Abughosh, Susan M.
    Holmes, Holly M.
    Candrilli, Sean D.
    Johnson, Michael L.
    CANCER, 2023, 129 (07) : 1051 - 1063
12345